Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals Inc (ELDN) is a clinical-stage biotechnology company pioneering targeted immunosuppressive therapies through its anti-CD40L antibody tegoprubart. This page serves as the definitive source for verified updates on the company's clinical developments, regulatory milestones, and research advancements.
Investors and medical professionals will find timely updates on kidney transplant trials, islet cell transplantation studies for diabetes, and xenotransplantation research. Our curated news collection includes FDA communications, partnership announcements, and peer-reviewed publication highlights related to ELDN's novel approach to immune-mediated conditions.
All content undergoes rigorous verification to ensure accuracy in reporting clinical trial phases, scientific collaborations, and therapeutic mechanism updates. The resource is particularly valuable for tracking progress in reducing transplant rejection risks and improving autoimmune disease management through CD40 pathway modulation.
Bookmark this page for structured access to ELDN's evolving clinical pipeline, including safety profile updates for tegoprubart and expansion into new therapeutic applications. Check regularly for objective reporting on this innovative approach to immune system regulation.
Eledon Pharmaceuticals announced positive topline results from a Phase 2a clinical trial of tegoprubart in patients with amyotrophic lateral sclerosis (ALS). The study demonstrated that tegoprubart was well-tolerated with no serious drug-related adverse events. Dose-dependent reductions in pro-inflammatory biomarkers were observed, alongside a trend in slowing disease progression as assessed by ALSFRS slope. The trial enrolled 54 patients across 13 sites in the US and Canada, with promising implications for future clinical studies.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q1 2022 results, showcasing a net loss of $9.9 million ($0.69 per share), up from a loss of $8.5 million ($0.57 per share) in Q1 2021. The increase in losses was primarily due to higher R&D expenses, which totaled $6.6 million, compared to $5.7 million last year. Significant developments include the completion of patient enrollment for the Phase 2a tegoprubart study in ALS, with topline data anticipated in June 2022, and the first patient dosed in the IgA Nephropathy trial, expanding the clinical footprint internationally.
Eledon Pharmaceuticals has initiated a multicenter, open-label Phase 2a study for its drug, tegoprubart, aimed at treating patients with IgA Nephropathy (IgAN), a kidney condition affecting over 150,000 Americans. The study will assess the drug's safety and efficacy based on changes in urine protein levels over 24 weeks, with additional assessments through 96 weeks. Eledon's CEO highlighted the potential of tegoprubart to improve current treatment standards for IgAN, a disease with significant unmet medical needs.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its Q1 2022 financial results on May 12, 2022, following market close. A conference call and webcast are scheduled for 4:30 p.m. ET to discuss these results. Eledon focuses on developing treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Their lead candidate, tegoprubart, targets the CD40 Ligand pathway and shows potential across various therapeutic areas. After the live event, the webcast will be archived on Eledon's website.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company specializing in treatments for transplant and autoimmune conditions, announced its participation in a fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, at 2:00 p.m. ET. Interested individuals can register for the webcast here. A replay will later be available on the company's website.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on organ transplantation and autoimmune diseases, announced that Dr. Steve Perrin will present at NobleCon18 on April 21, 2022 at 11:30 a.m. ET.
The company is advancing its lead compound, tegoprubart, targeting the CD40 Ligand pathway, used for treating transplant patients and autoimmune conditions. A replay of the presentation will be accessible on the Noble Capital Markets’ website and Channelchek.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company, announced it will host its first R&D Day on April 28, 2022, from 10 a.m. to 12 p.m. ET. This virtual event will feature Eledon’s senior management team alongside leading experts discussing the investigational drug tegoprubart and the potential of CD40 Ligand targeted immunotherapy for conditions like ALS and kidney transplantation. The presentation will include insights from prominent professionals in neurology and renal medicine. For more details, visit the company's R&D Day website.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2021 results, marking a significant year of progress.
They fully enrolled a Phase 2a trial for tegoprubart in ALS and initiated multiple other clinical studies. The cash balance stands at $84.8 million, expected to fund operations into 2024.
Net losses were $34.5 million for 2021, up from $22.8 million in 2020, primarily due to increased R&D expenses.
Topline data from the ALS trial is expected in 2Q 2022.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its fourth quarter and full year 2021 financial results on March 24, 2022, after market close. The management team will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Eledon focuses on developing innovative treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative disorders. Its lead product, tegoprubart, targets the CD40 Ligand pathway, offering potential benefits for patients requiring transplants or suffering from ALS.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced the completion of enrollment for all cohorts in its Phase 2a study of tegoprubart in Amyotrophic Lateral Sclerosis (ALS). The company received USAN approval for the generic name tegoprubart for its lead asset AT-1501. With a robust capital position, Eledon is well-funded to support operations into 2024. Anticipated clinical data readouts in 2022 include topline results from the ALS trial and studies in kidney transplantation and IgA nephropathy. Eledon aims to advance precision therapies targeting the CD40 ligand pathway.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
